| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.95B | 5.38B | 9.62B | 7.32B | 3.33B | 3.13B |
| Gross Profit | 609.00M | 84.24M | 1.20B | 3.08B | 1.01B | 996.85M |
| EBITDA | 722.94M | -9.11M | 897.06M | 2.87B | 875.13M | 742.46M |
| Net Income | -21.16M | -1.18B | 1.57B | 2.69B | 123.67M | 375.76M |
Balance Sheet | ||||||
| Total Assets | 17.15B | 16.61B | 18.27B | 15.46B | 10.97B | 10.45B |
| Cash, Cash Equivalents and Short-Term Investments | 1.93B | 1.19B | 889.90M | 1.50B | 439.27M | 746.72M |
| Total Debt | 3.76B | 3.62B | 4.28B | 3.32B | 2.52B | 3.69B |
| Total Liabilities | 6.88B | 6.41B | 8.61B | 7.27B | 5.17B | 5.98B |
| Stockholders Equity | 10.00B | 9.96B | 9.41B | 7.98B | 5.63B | 4.27B |
Cash Flow | ||||||
| Free Cash Flow | 104.31M | -983.72M | -823.96M | 646.20M | -609.41M | -51.56M |
| Operating Cash Flow | 894.46M | 702.07M | 1.33B | 1.91B | 344.26M | 798.91M |
| Investing Cash Flow | -297.18M | -1.57B | -2.78B | -1.42B | -666.59M | -863.57M |
| Financing Cash Flow | -394.05M | 1.24B | 623.91M | 611.89M | 50.21M | 177.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $18.40B | 37.12 | 9.87% | ― | -10.07% | ― | |
67 Neutral | $7.29B | 10.66 | 12.24% | 5.19% | -3.33% | -19.59% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | $15.86B | -87.98 | -0.21% | 1.20% | -23.92% | 90.47% | |
52 Neutral | $14.09B | -11.45 | -10.44% | 12.66% | -19.65% | -157.13% | |
52 Neutral | $9.49B | -10.07 | -9.48% | 2.85% | -5.32% | -1108.29% | |
45 Neutral | $7.57B | -90.89 | -1.48% | ― | -3.59% | -126.16% |
On October 25, 2025, Albemarle Corporation entered into a Stock Purchase Agreement to sell part of Ketjen’s common stock to ChemCat AcquisitionCo, LLC, and contribute the remaining shares to ChemCat Holdings, LP, affiliated with KPS Capital Partners. This transaction, expected to yield $536 million in cash for Albemarle, will also involve a goodwill impairment charge of $181.5 million for the Refining Solutions unit. Additionally, Ketjen has agreed to sell its stake in Eurecat S.A. to Axens SA for €105 million, with the transaction expected to close in the first half of 2026. Albemarle anticipates receiving approximately $660 million in total proceeds from these transactions, which will be used for debt reduction and other corporate purposes.